XENT News and Press, Intersect ENT Inc. From 05/10/21

Intersect ENT, Inc. (XENT) Q1 2021 Earnings Conference Call May 10, 2021 08:30 AM ET Company Participants Randy Meier - Executive Vice President & Chief Financial Officer Tom West - President & Chief Executive Officer Conference Call Participants Robbie Marcus - JPMorgan Richard Newit...

Intersect ENT (XENT): Q1 Non-GAAP EPS of -$0.51 misses by $0.08; GAAP EPS of -$0.61 misses by $0.21.Revenue of $24.3M (+22.5% Y/Y) beats by $0.76M.Intersect ENT is raising its full year 2021 revenue guidance from a range of $116 million - $120 million to a range of $117 million - $121 million...

— Increases 2021 Revenue Guidance to $117 Million to $121 Million — Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for the fi...

Mark L. Alley to serve as Vice President of Sales Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the appointment of Mark L. Alley as Vice President of S...

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, announced that the Company has changed the date of its previously scheduled first quarter 2021 financial results announcement and con...

Study Initiates with Registration on ClinicalTrials.gov Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that it began the process of initiating the...

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that it will release first quarter 2021 financial results on Tuesday, May 4, 2021. The Company expects to issue the r...

- Resignation of Anthony Vernon and Appointment of Elisabeth Sandoval-Little - Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Anthony Vernon has re...

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced Neil Hattangadi, M.D., M.Sc. joined the Intersect ENT Board of Directors. Dr. Hattangadi will serve as a member of th...

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Tom West, President & Chief Executive Officer, and Randy Meier, Executive Vice President & Chief Financi...